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Abstract
Background: Malaria remains a major cause of morbidity and mortality among children under five
years of age in Nigeria. Most of the early treatments for fever and malaria occur through self-
medication with anti-malarials bought over-the-counter (OTC) from untrained drug vendors. Self-
medication through drug vendors can be ineffective, with increased risks of drug toxicity and
development of drug resistance. Global malaria control initiatives highlights the potential role of
drug vendors to improve access to early effective malaria treatment, which underscores the need
for interventions to improve treatment obtained from these outlets. This study aimed to determine
the feasibility and impact of training rural drug vendors on community-based malaria treatment and
advice with referral of severe cases to a health facility.
Methods:  A drug vendor-training programme was carried out between 2003 and 2005 in
Ugwuogo-Nike, a rural community in south-east Nigeria. A total of 16 drug vendors were trained
and monitored for eight months. The programme was evaluated to measure changes in drug
vendor practice and knowledge using exit interviews. In addition, home visits were conducted to
measure compliance with referral.
Results: The intervention achieved major improvements in drug selling and referral practices and
knowledge. Exit interviews confirmed significant increases in appropriate anti-malarial drug
dispensing, correct history questions asked and advice given. Improvements in malaria knowledge
was established and 80% compliance with referred cases was observed during the study period,
Conclusion: The remarkable change in knowledge and practices observed indicates that training
of drug vendors, as a means of communication in the community, is feasible and strongly supports
their inclusion in control strategies aimed at improving prompt effective treatment of malaria with
referral of severe cases.
Background
More than a million people die of malaria each year and
most of them occur in Africa [1]. In Nigeria, malaria is one
of the leading causes of morbidity and mortality and a
major public health problem with a prevalence rate of
infection of 919/100,000. It accounts for 40% of disease
burden (clinical out/inpatient cases) reported at the pub-
lic health facilities, for 30% of all childhood deaths, and
is associated with 11% of maternal deaths. The loss to the
economy, as a direct result of malaria infections, has been
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estimated as Naira 132 billion (£530 million) [2]. Malaria
is both a cause and a consequence of poverty in Nigeria.
In order to treat the disease, people seek treatment from a
broad spectrum of public and private healthcare providers
[3,4]. Around 60% of all malaria episodes in sub-Saharan
Africa (SSA) are initially treated by private providers,
mainly through the purchase of drugs from shops and
drug peddlers [3-5]. Reasons for preferring drug shops
include geographical accessibility, shorter waiting times,
more reliable drug stocks, longer opening hours, friendly
staff, greater confidentiality, lower cost and because they
do not charge a separate fee for advice [6,7].
One of the problems associated with treatment by these
patent medicine dealers is that there is poor knowledge
and poor dispensing behaviour in relation to childhood
malaria episodes [8]. These treatments are often incorrect
[9-12] and the ineffectiveness of these early practices rep-
resents a major problem, since majority of malaria mor-
tality occur within the first 48 hours of illness [13]. These
practices may also contribute to the spread of anti-malar-
ial drug resistance [14].
In Nigeria, patent medicine vendors (PMV's) are usually
the first choice in health care and are a recognized primary
source of orthodox drugs for both rural and urban popu-
lations, especially the poor [15-17]. In addition to selling
drugs, they are also a major source of advice about illness
and drug therapy [18].
The patent medicine vendor can be defined as a person
without formal pharmacy training, who sells orthodox
pharmaceutical products on a retail basis for profit [19].
The primary function of the PMV is a business and like
any other successful business person, the PMV tries to
respond to customer demand, hence the bulk of cus-
tomer-PMV interactions simply involve the selling of
medications requested by the customer [20]. Over-the-
counter (OTC) drugs are the only drugs authorized to be
sold by the vendors, but they generally sell all types of
drugs as determined by their financial capability [21].
These range from paracetamol and chloroquine in large
tins to antibiotic, psychotropic drugs, narcotics, toxoids,
and antihypertensives, that are outside the scope of their
license [22]. In addition, the PMV obtains their drug sup-
plies through both formal and informal channels includ-
ing large retail and wholesale pharmacies in major cities,
direct from pharmaceutical companies, and through visit-
ing company representatives [22]. There are also reports
that these drugs may be ineffective, counterfeit or expired
[21].
In addition, most of the anti-malarial drugs purchased
from PMVs in a study in Nigeria were for children [23].
Since private drug retailers are often the primary source of
treatment for malaria in the home, this underscores the
need for improved practices within these outlets, taking
into consideration the problems associated with using
them.
The results of the formative stage (pre-intervention phase)
of this study [8] showed that there was poor knowledge
and poor dispensing practices in relation to childhood
malaria among these drug vendors in the study area,
although referral of severe malaria was common there
were those that will not refer to a health facility. History
was rarely taken before dispensing drugs and verbal advice
was never given to care takers.
Based on these results an intervention programme was
developed to determine the feasibility of training drug
vendors to provide appropriate treatment for childhood
malaria, to take on an advisory role and to refer severe
cases of malaria promptly, with a view to reducing child-
hood morbidity and mortality and achieving the health
related Millennium Development Goals 4.
Thus this report is part of a larger study designed to
improve home management of childhood malaria and




The study area has previously been described [8]. Malaria
is holoendemic with a high transmission rate all the year
round and an average incidence rate of 20%. The main
malaria vector is Anopheles gambiae and Plasmodium falci-
parum is responsible for more than 90% of all malaria
infection [24]
The intervention programme
The intervention programme commenced on the 30th
December 2003 for a period of 18 months, until June
2005. The total number of drug vendors had increased
from 13 at time of baseline study[8] to 16 by intervention
period and all belonged to the PMV association.
The main components of the programme were training of
drug vendors, community information activities, moni-
toring and evaluation of the programme. In recognition of
the prominent role which traditional, administrative and
political leaders play in ensuring community participa-
tion and successful implementation of an intervention
programme, a series of sensitization meetings were held
in the community. Having obtained the support of the
community leaders, meetings were then held with the
members of drug vendors association to gain their coop-
eration. Enough trust was built with the drug vendors dur-Malaria Journal 2009, 8:260 http://www.malariajournal.com/content/8/1/260
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ing the formative phase. In addition, the results of the
formative phase were fed back to them and they showed
great interest in the intervention.
A core group known as Project-Community Communica-
tion Group (PCCG) was formed. The composition of the
PCCG included women leaders, opinion leaders, repre-
sentatives of patent medicine vendors and project mem-
bers. The main aim was to promote community
participation and for the group to help in the design,
implementation and monitoring of the project and also to
act as a link between the research team and the commu-
nity.
Some members of the research team, representatives of
drug vendors and a graphic artist worked together to
design the job aids which included, age-specific dose
guides for treatment of malaria with chloroquine (Figure
1) and paracetamol. Age groups are identified by pictures
of children at different developmental stages, which are
easier to recognize than exact ages or weights. The number
of tablets is also represented pictorially.
Age-specific rubber stamps depicting correct doses of
chloroquine in children of different ages with different
colours of handles for the different age groups for easy rec-
ognition were produced. Posters were also produced
depicting a child with mild and severe malaria with a list
of the clinical symptoms. This was to aid drug vendors in
diagnosis of severe malaria requiring referral. It was also
to serve as client awareness poster to help caretakers dif-
ferentiate between mild and severe malaria
The community information activities aimed to create
awareness of the programme, give information on recom-
mended anti-malarial drug policy, importance of appro-
priate early treatment and symptoms of severe disease
requiring referral to a health facility. This was done
through community meetings, distribution of posters,
which were placed in strategic places in the community,
and drama groups, which performed regularly. The results
of this will be published elsewhere.
Training of drug vendors
Drug vendors were trained in a series of two workshops
each lasting three days. To ensure full participation, all the
training activities took place on days that were not market
days, when they were considered very busy. The participa-
tory approach was adopted for the training, which empha-
sized culturally appropriate methods, such as role play.
Training focused on improving their age-specific dispens-
ing practices for chloroquine, which was the recom-
mended anti-malarial at time of study, asking relevant
history questions before giving treatment instructions as
well as effective communication skills to enable them give
accurate verbal advice to caretakers. They were trained to
recognize symptoms requiring referral and were taught to
record all referrals on a notebook by writing the child's
name, the date and reasons for the referral. Referral was
facilitated by giving the caretakers referral note stamped
with a referral stamp and also by informing nearby hospi-
tals to recognize the referral stamp as that of a child
requiring urgent attention.
The caretakers were to choose the hospitals of their choice,
since baseline results showed the local health centre was
not being utilized for reasons that included the lack of a
doctor. To measure compliance with referral, some com-
munity members chosen by the PCCG, were detailed to
follow up the referred patients at home to confirm com-
pliance.
In addition, sessions on reading the doctor's prescription
was included based on drug vendors request and the fact
that patients will eventually end in their shops to purchase
drugs. At the end of the workshop, they were given job
aids such as age-specific dose guides for malaria treatment
to be hung up on the wall of their shops, to serve as
reminders before dispensing drugs. They were taught to
stamp the dispensing envelopes with the right dose for the
age of sick child, to serve as a visual reminder of the verbal
advice given to caretakers.
At the end of the training, certificates of participation were
distributed to all participants. Drug vendors appreciated
the certificates as this will elevate their status within the
community as well as boost sales of drugs. They were nei-
ther charged nor remunerated for their participation.
Monitoring and evaluation
This was carried out by some members of the research
team and trained research assistants. Monitoring and face-
to-face supportive supervision for drug vendors, designed
to reinforce skills was carried out for a period of eight
months. Unannounced face-to-face observations were
conducted to monitor health care providers performance
after training. Later supportive feedback was provided for
problems they were not aware of and important issues
raised were solved to help them integrate the new knowl-
edge and skills into their daily practices.
The programme was evaluated by conducting three
rounds of exit interviews on all trained PMVs. Immedi-
ately after leaving the PMVs' outlet, the caretaker was
interviewed at a location away from the shop, using a pre-
structured form, which was developed to record all the
behaviours the PMVs were expected to perform at the end
of training. This is with regards to history questions asked,
treatment given, whether reference was made to the doseMalaria Journal 2009, 8:260 http://www.malariajournal.com/content/8/1/260
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Pictogram of chloroquine dosing schedule for children of different ages Figure 1
Pictogram of chloroquine dosing schedule for children of different ages. Age groups are identified by pictures of chil-
dren at different developmental stages, which is easier to recognize than exact ages or weights. The number of tablets is also 
represented pictorially.Malaria Journal 2009, 8:260 http://www.malariajournal.com/content/8/1/260
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guides provided, if stamped envelopes were given and
type of verbal advice given if any.
In-depth interviews (IDI) were conducted with the PMVs
using IDI guide to explore their knowledge, beliefs, and
stated treatment practices for mild and severe malaria, as
well as the referral practices for severe malaria. The inter-
view was conducted in the morning hours on non-market
days (when the patient flow to the drug sellers' stores was
minimal) by two community health nurses from the
Health Visiting Unit of the Department of Community
Medicine, who also conducted the pre-intervention phase
interviews. Each interview lasted between 60 and 75 min-
utes. The interview was tape-recorded and notes taken.
In addition, a review of the PMVs' referral records was
conducted. The review noted the total number of cases
referred during the study period by drug vendors and the
main reasons for referral. The places the patients were
referred to was also noted. To measure compliance with
referral, some community members chosen by the PCCG,
were detailed to follow up the referred patients at home to
confirm compliance and this information was collected
from the PCCG members.
Data analysis
Data entry and statistical analysis was conducted using
EPI-INFO version 6.04 and SPSS statistical packages ver-
sion 15. Chi-square test was used to test for any significant
differences between proportions before and after inter-
vention.
For the qualitative data, the transcriptions was organized
under thematic headings and later developed into an eth-
nographic summary with illustrative quotes. The trajecto-
ries of their response to questions were captured with a
trajectory tree and then the different ranges of opinions,
perceptions and stated practices were noted.
Ethical considerations
Ethical approval was sought and obtained from the Ethi-
cal Committee of The University of Nigeria Teaching Hos-
pital, Enugu (UNTH). The research objectives and
methods were explained to individual respondents and
verbal informed consent to tape-recording the interviews
was obtained from the study participants before the inter-
view commenced.
Confidentiality of all information obtained from partici-
pants was maintained by not allowing information on the
respondents' identities to be accessible to non-members
of the research team.
Results
A total of 16 patent medicine vendors (PMVs), registered
with the association were trained. They comprised eleven
male and five female practitioners and the age range was
from 26 to 42 years. The majority (14/16, 87.5%) had
attained primary education while only (2/16, 12.5%) had
secondary education. Only one, who is a trained nurse,
had received any formal training in drug use. Generally,
they were willing to participate in the programme and all
16 of them were trained giving 100% participation rate.
They acknowledged the importance of profit as a motive
for their drug dispensing habit, preferring a sale of single
tablets (incomplete course) to no sale at all. However,
they were advised to sell only full courses of anti-malarials
to caretakers and the sale of single tablets was discour-
aged. They were eager to receive further training and to
broaden the scope of their therapeutic activities.
Table 1: Exit interview for drug vendors
1st month (n = 190) 4th month (n = 100) 8th month (n = 188) X2 for trends
P value
Correct history questions asked 83 (43.7%) 75 (75%) 173 (92%) 101.3
p < 0.001*
Reference to dose guides 80 (42.1%) 69 (69%) 171 (90.9%) 100.7
P < 0.001*
Correct treatment given 80 (42.1%) 69 (69%) 171 (90.9%) 100.7 p < 0.001*
**Correct verbal advice 71 (37.3%) 63 (63%) 167 (88.8%) 106.7, p < 0.001*
Stamped envelope given 83 (43.7%) 63 (63%) 174 (92.6%) 102.6, p < 0.001*
* = significant.
** = correct advice was regarded as (telling clients how to take their drugs, side effects of the drugs and what to do if symptoms persists)Malaria Journal 2009, 8:260 http://www.malariajournal.com/content/8/1/260
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The result of the exit interviews is shown in Table 1. There
was a steady increase in correct practices over time and
this was found to be statistically significant, p < 0.05. As
the months went by, more drug vendors asked correct his-
tory questions, made reference to dose guides before dis-
pensing anti-malarials, gave correct treatment of
chloroquine accompanied by accurate verbal advice and
stamped dispensing envelopes with correct rubber stamps
for age of the sick child.
Causes and mode of transmission of malaria
During the pre-intervention phase [8], some of the PMVs
had more than one perception about the cause of malaria.
These include mosquitoes (10/13, 76.9%), sun (6/13,
46.2%) and drinking dirty water (4/13, 30.8%). Other
causes mentioned by less than four vendors, included eat-
ing fried/oily food, cold and body contact. When asked to
state how the sun causes malaria, one of them explained "
the sun can cause malaria when it shines directly on the child".
However, after the intervention, (15/16, 93.8%) of drug
vendors knew mosquitoes as a cause of malaria, (1/16,
6.3%), still attributed malaria to eating of oily/fried food.
In the pre-intervention, the mode of transmission was
also not quite clear. However, in the post-intervention
phase, the majority had acquired correct knowledge about
mode of transmission. According to one vendor" when
mosquito bites a person carrying the parasite already, it carries
the parasite and transfers it to a healthy person when it bites
that person. In that way it transfers the parasite from a sufferer
to a healthy person and malaria starts".
Symptoms and signs of malaria
During the pre-intervention phase, when asked to discuss
the symptoms of malaria, drug vendors correctly identi-
fied them to be fever (9/13, 69.2%), headache (8/13,
61.5%), weakness (7/13, 53.8%), loss of appetite (7/13,
53.8%) and restlessness (6/13, 46.2%) for mild malaria.
Other less commonly noted symptoms included deep yel-
lowish discoloration of urine, chills, vomiting, and stom-
ach upset, dreaming, and excessive sweating. However,
following training, there was an increase in recognition of
malaria as (14/16, 87.5%) of vendors identified fever as a
major symptom of malaria followed by loss of appetite
(68.8%), chills (62.5%), headache (62.5%), weakness
(56.3%), and vomiting (50%). They were less knowledge-
able about symptoms of severe illness before intervention.
Persistent fever and convulsions, which were recognized
by 38.5% and 30.8% of vendors, respectively, were the
popular answers. Also mentioned were yellowish discol-
oration of the skin (23.1%) and unconsciousness
(15.4%). But the intervention had a positive impact on
the recognition of signs of severe malaria. In the post-
intervention, most drug vendors could now list the cardi-
nal signs, such as convulsions (87.5%), persistent fever
(68.8%), unconsciousness (62.5%), dryness of skin
(62.5%), inability to stand/sit (56.3%), yellowish discol-
oration of the skin (50%), fast breathing (43.7%) and
coke-colored urine (43.8%). The relationship between
malaria and convulsion, which was previously vague, was
also better understood as shown in this quote "malaria
gives very high fever and convulsion occurs from very high fever,
again when malaria enters the brain of the child, it causes con-
vulsion"
Treatment practices
During formative research, when asked about how treat-
ment decisions are made (8/13, 61.5%) responded they
dispensed what customers demand. Only (2/13, 15.4%)
did take some form of history, by asking about age of the
child only, before giving drugs and none gave any verbal
advice to caretakers. Furthermore, a majority (11/13,
84%) used chloroquine as their first-line drug, in addition
to analgesics in the form of paracetamol, as an adjunct to
specific anti-malarial drugs for the treatment of mild
malaria. In general the knowledge with regards to drug
dosages and duration of treatment was grossly inadequate
and none dispensed anti-malarial drugs correctly.
However, the intervention resulted in an increase in
knowledge and correct practices as shown by results of exit
interviews in Table 1 and the qualitative data. The number
that will take a history rose from 43.7% in the first month
to 75% by the fourth month after training and to 92%
after 8 months. A female drug vendor in an IDI com-
mented that "you do not commence treatment immediately,
you first take history, if he has not received any treatment you
then give them some drugs and tell them how to take it." The
majority also refered to their age-specific dose guides
before administering any treatment, as one of them noted
"when the mother brings the child, I will welcome the mother,
sit her down, ask the mother when the sickness started, what
type of treatment she has given. Then after this I will bring the
chart so that I will give the correct dose according to the age of
the child. Yet another remarked "I look at the drug guides you
gave us to treat these children". Commenting on the efficacy
of treatment one of them observed that "if they bring the
child on time this treatment works fast and the child recovers
immediately after 3 days".
The percentage of anti-malarial drug sales where an ade-
quate amount of chloroquine was sold rose from 42.1%
one month after training to 69% after four months and to
90.9% after 8 months. It was noted that the same drug
vendors who made reference to their dose guides also dis-
pensed chloroquine correctly. Generally there was a
steady increase in correct practices over the months with
regards to history questions asked, reference to dose
guides, treatment given, verbal advice and stamping of
dispensing envelopes. All these observed differences were
statistically significant (p < 0.05) as shown in table 1.Malaria Journal 2009, 8:260 http://www.malariajournal.com/content/8/1/260
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Referral practices
Prior to the intervention, most drug vendors indicated
that they also made use of chloroquine and paracetamol
as the major drugs for the treatment of severe malaria.
None did refer a child with severe malaria to a health facil-
ity, unless he starts convulsing. There was a gap in knowl-
edge of severe symptoms requiring referral. After the
intervention, most had learnt that severe cases should be
referred immediately. As one vendor remarked "if it is
severe malaria it is above my scope, I will tell them to go to the
hospital. You cannot treat this type because it is beyond my
scope". Yet another explained "when we use the system we
learnt from the training and treat mild malaria, if it does not
respond, we refer them to the hospital on time".
A total of 132 cases were referred during the study period
by drug vendors out of which 115 (80%) complied. The
main reasons for referral were high fever, weakness and
vomiting. A majority 50 (47.6%) of the referred patients
went to Parklane General hospital, while 37 (35.2%) of
them went to the University of Nigeria Teaching Hospital,
both situated in the urban area about 20 kilometers away.
Nine (8.6%) used private clinics and the community
health center. All severe cases were referred.
Discussion
The training interventions were aimed at building the
knowledge and skills that will enable PMVs to provide
better treatment for malaria and refer severe malaria cases.
This study shows that the training improved their knowl-
edge and correct practices. These results are rather encour-
aging, considering the difficulty involved in changing
private sector practices. As noted by a WHO study group,
achieving rational prescribing in the private sector is
"notoriously difficult" due to influences from patient
demand, drug advertising and profit margins [25].
A majority of them were able to provide anti-malarials in
the right dose and for the right duration. No doubt this is
likely to improve the effectiveness of anti-malarial treat-
ment, and hence reduce the development of drug resistant
and eventual cost of treatment. The result is similar to
what was obtained in Kenya [26], where peer education
supplemented with job aids was able to produce improve-
ments in the selling of appropriate drugs in appropriate
amounts.
The intervention also showed that drug vendors were able
to give correct verbal advice to their patients in such a way
that the customers understand and can follow the advice.
However, as has been noted in Nigeria [20], there may be
concern that profit motive might muffle the interest in
medication counseling as the vendors may not want to
waste their time giving advice to the clients when there is
rush in their shops.
The referral of severe cases of malaria to a health facility
also improved. This is particularly encouraging as
increased trend in morbidity from severe malaria has been
noted in Nigeria [27] and early referral from PMVs is likely
to improve the outcome of severe malaria.
The training programme focused on chloroquine because
at the time of the study it was the recommended first-line
treatment and the only anti-malarial drug available in the
majority of shops in the study area. The new policy, which
recommended a change to artemisinin-based combina-
tion therapy (ACT), was officially inaugurated in May
2005 [28], by which time the intervention programme
had ended. The policy change became necessary as the
therapeutic efficacy of chloroquine had deteriorated.
However, the choice of drug in this study was not as per-
tinent as establishing the fact that community education
on drug use and referral of severe cases, can be effectively
carried out by patent medicine vendors.
The improvement in the knowledge of the vendors sug-
gests that they are very receptive and that their training is
feasible. They are, therefore, likely to be useful in health
interventions when given the appropriate training.
The interpretation of results of this study is limited by the
fact that it lacks randomization. Nevertheless the data
shows a highly probable relationship between the intro-
duction of a specific training programme and changes in
PMV's behavioural practices, which are strongly related to
the content of the intervention. In addition there were no
other local sources of information on anti-malarials dur-
ing the study period, other than biased information from
pharmaceutical companies.
Generally the advantages of training to drug vendors
would be a possible increase in prestige and OTC sales,
especially if certificates were issued at the end of the train-
ing as was the case in our study. The advantages to rural
communities, would be that they would receive more reli-
able advice when they purchase OTC drugs. If carried out
effectively such a programme could reduce morbidity and
mortality in these communities, by initiating prompt
appropriate treatment of malaria with early referral of
severe cases to a health facility. The potential role of pri-
vate retailers as partners for malaria control has long been
recognized [29-33] and success has been achieved in
training them [20,26] and it was shown that PMVs receiv-
ing job aids had significantly better malaria knowledge
and prescribing practices than those that did not [34].
However, key challenges to lasting success in Nigeria, are
issues such as: high vendor turn-over rates in shops, sus-
tainability of the change, need for continuous re-training
and patient compliance with recommended treatment
regimensMalaria Journal 2009, 8:260 http://www.malariajournal.com/content/8/1/260
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Conclusion
The primary goal of malaria control is to reduce morbidity
and mortality through prompt diagnosis and adequate
treatment. The focus of delivery of such service has been
through the formal health facilities. However, such set-
tings, where treatment is provided by trained personnel,
represents only a small part of the providers of care for
malaria patients
The retail sector seems to have the greatest potential in
improving access to anti-malarials. This is because this
sector is generally more accessible geographically and
treatment from this source is cheap and involves less time.
The findings of this study strongly support the inclusion
of patent medicine vendors in malaria control strategies in
form of public private partnership and are in line with the
philosophy of primary health care, which is noted for
advocating incorporation of local human resources into
healthcare efforts. This was demonstrated in Tanzania
[35] and in Nigeria with other health interventions [36].
Drug vendors should, therefore, be made partners in the
health care network, since they are likely to continue as a
major source of anti-malarial drugs for most rural com-
munities in the foreseeable future.
With the newly introduced high cost ACT, a policy option
to improve diagnosis and prescribing pattern in private
sectors will be to train PMVs in the appropriate use of
ACT, using pictorial aids and dose guide as in this study.
Although there is no guarantee that the PMVs will perform
as well as with chloroquine, it is believed that If well taken
by the PMVs, it is likely to decrease inappropriate drug
prescribing, use, costs and resistance to ACT. It may also
enhance the delivery of ACT for malaria treatment.
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